市场调查报告书
商品编码
1417598
全球眼科雷射市场评估:依产品类型、应用、最终用户、地区、机会、预测(2017-2031)Ophthalmic Lasers Market Assessment, By Product Type, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球眼科雷射市场规模预计到2023年将达到15.1亿美元,到2031年将达到23.8亿美元,2024-2031年预测期间复合年增长率为5.86%。全球眼科雷射市场是眼科器械市场中成长最快的市场。全球眼科雷射市场受到眼科疾病盛行率增加、老年人口增加以及雷射设备技术进步等因素的推动。由于萤幕时间增加、生活方式改变、营养缺乏和慢性疾病等因素,全球眼科患者数量不断增加。这些因素推动了对眼科雷射设备的巨大需求。
预计老龄化人口的成长将增加有视力障碍需求的人数。此外,由于眼科疾病是慢性病的主要合併症,糖尿病和高血压等慢性病的盛行率不断上升,预计将吸引雷射设备的需求。许多技术进步,例如设计优化、功能改进和副作用减少,都有助于眼科雷射设备不断增长的需求。政府的利好政策加强了医疗基础设施和设备的供应,促进了市场。与传统治疗相比,雷射眼科治疗具有多种优势,包括疼痛少、疗效高、住院时间短、无需切口等,使其成为治疗白内障、AMD、青光眼等眼部疾病的理想选择,深受人们喜爱。然而,雷射治疗成本高昂且缺乏熟练专业人员等因素可能会阻碍预测期内的市场成长。
2023 年 4 月,Johnson & Johnson Vision 宣布其新型 ELITA Femtosecond Laser已获得 FDA 510(k) 许可。过去 20 年来,Johnson & Johnson Vision 一直是眼科设备产业的领导者,拥有前景看好的产品组合。ELITA Femtosecond Laser具有低每脉衝能量、超快雷射重复率和小光斑尺寸,提高了外科医生的速度和准确性。
由于不健康的生活方式、营养缺乏和长时间看萤幕,眼科疾病的盛行率不断上升,推动了眼科雷射市场的需求。最常见的眼部疾病包括近视、屈光不正、白内障、糖尿病视网膜病变、青光眼和老年黄斑部病变。大多数外科医生建议针对这些情况进行雷射治疗,因为它已被证明是有效的并且需要较少的术后护理。
例如,根据世界卫生组织2023年8月发布的情况说明书,全球约有22亿人患有近视力障碍或远视力障碍,其中约10亿人患有远视力障碍;8840万人因白内障失明, 8840万人患有屈光不正,800万人患有老年黄斑部病变,770万人患有青光眼,390万人患有糖尿病性视网膜病变。近距离视力障碍的主要原因是老花眼,影响约 8.26 亿人。
老化人口的增加,更容易患上眼部疾病,大大推动了对眼科雷射治疗的需求。随着年龄的增长,与年龄相关的因素导致眼部疾病的可能性也会增加。日本等国家老年人口较多,因此占了很大一部分市场。根据世界卫生组织的数据,到2030年,全球总人口将达到14亿,六分之一的人将年龄在60岁以上。世界卫生组织估计,到 2020 年,老年人口将达到 10 亿。预计到 2050 年,这一数字将增加一倍。从2020年到2050年,80岁及以上的人口预计将增加四倍,达到约4.26亿人。根据国家健康与老化趋势研究,美国 71 岁及以上的成年人中有 27.8% 有视力障碍。
本报告针对全球眼科雷射市场进行研究和分析,提供市场规模和预测、市场动态、主要参与者现状和前景等。
Global ophthalmic lasers market size was valued at USD 1.51 billion in 2023, and is expected to reach USD 2.38 billion in 2031, with a CAGR of 5.86% for the forecast period between 2024 and 2031F. The global ophthalmic lasers market is a fast-growing market within the ophthalmic devices market. The global ophthalmic lasers market is driven by factors such as the growing prevalence of ophthalmic disorders, rising geriatric population, and technological advancements in laser devices. The number of ophthalmic patients is increasing globally owing to factors such as longer screen time, lifestyle changes, lack of nutrition, and chronic diseases. These factors are driving huge demand for ophthalmic laser devices.
Growth in geriatric population is expected to increase the number of people who require vision impairment. Additionally, the growing prevalence of chronic diseases, such as diabetes and hypertension, are expected to draw demand for laser devices as ophthalmic disorders are prominent comorbidities with chronic diseases. Technological advancements like design optimization, functionality improvement, reducing side effects, and many others are favoring the growth in demand for ophthalmic laser devices. Favorable government policies strengthen the healthcare infrastructure and medical device availability, promoting the market. Laser ophthalmic treatments have several benefits over conventional treatment methods such as less pain, high effectivity, shorter hospital stay, and no need for incision, thus preferred over conventional methods for managing ophthalmic diseases like cataracts, AMD, and glaucoma. However, factors like the high cost of laser therapies and the lack of skilled professionals may hinder market growth during the forecast period.
In April 2023, Johnson & Johnson Vision announced that it had received FDA 510(k) clearance for its new ELITA Femtosecond Laser FDA 510(k) clearance to create LASIK flaps. Johnson & Johnson Vision has been a leader in the ophthalmic devices industry for the last two decades with a promising product portfolio. The ELITA Femtosecond laser flap offers low energy per pulse, with ultra-fast laser repetition rate and small spot size, facilitating the surgeon's speed and accuracy.
The growing prevalence of ophthalmic disorders due to unhealthy lifestyles, nutritional deficiency, and longer screen time is driving the demand in the ophthalmic lasers market. Most common ophthalmic disorders include myopia, refractive errors, cataracts, diabetic retinopathy, glaucoma, and age-related macular degeneration. Most surgeons recommend laser treatments for such diseases as they are proven effective and require a shorter post-operative care period.
For instance, according to a factsheet published by WHO in August 2023, around 2.2 billion individuals are suffering from near or distance vision impairment across the globe, out of which approx. 1 billion people suffer from distance vision impairment, 1 billion from blindness with cataracts, 88.4 million from refractive error, 8 million from age-related macular degeneration, 7.7 million from glaucoma, and 3.9 million from diabetic retinopathy. The major defect causing near vision impairment is presbyopia with a number of around 826 million patients.
The growing geriatric population that is highly prone to ophthalmic disorders is significantly driving the demand for ophthalmic laser treatments. With age, the chances of ophthalmic diseases increase due to age-associated factors. Countries such as Japan have a very high number of old age individuals and thus are contributing a major chunk of value share to the market. As per WHO data, by 2030, 1 out of 6 individuals worldwide will be above the age of 60 years, which is expected to be 1.4 billion population in total. WHO estimated 1 billion geriatric population in 2020. The number is expected to double (to 2.1 billion) by 2050. It is anticipated that between 2020 and 2050, the number of people 80 years of age or older will quadruple, reaching approx. 426 million counts. According to the National Health and Aging Trends Study, 27.8% of United States adults 71 years and older had visual impairments.
The femtosecond laser segment in global ophthalmic lasers is expected to dominate during the forecast period. Femtosecond laser is highly effective for the treatment of cataracts and refractive errors in the eye and, thus, is very commonly used. The growing prevalence of cataracts and technological advancements in femtosecond laser devices are some reasons for their dominance. Market players are investing in femtosecond laser technology to add cutting-edge products to their portfolio. For instance, in February 2023, Fluence announced the launch of Jasper Micro, a new addition to its Jasper range of femtosecond lasers. Jasper Micro is an air-cooled and very compact device with widespread applications like LASIK, PRK, and DNA transfection eye surgeries.
Asia-Pacific is home to developing countries, like India and China, which have a significantly high burden of ophthalmic diseases. The rising geriatric population with a higher affinity to ophthalmic diseases is driving the demand for ophthalmic lasers. The growing investment in the healthcare sector is helping expand the associated markets. Increasing investors' attention towards the region is opening opportunities for market expansion. Demand for efficient ophthalmic equipment in Asia-Pacific is increasing owing to rapidly evolving technologies. Heavy emphasis on preventive care and early intervention for ophthalmic disorders fuels the demand for ophthalmic lasers during the assessment period.
The healthcare infrastructure is developing and getting strengthened in nations across the globe and multiple attempts are being made to reduce the burden of ophthalmic diseases, for example, the integrated people-centered eye care (IPEC) initiative by WHO. Noval technology penetration in ophthalmic laser devices such as developments in femtosecond laser technology, the use of wavefront technology, and the use of adaptive optics are anticipated to strengthen the market dynamics in future years. These advances are anticipated to help surgeons perform more intricate and precise surgeries in the future through highly evolved lasers.
Market players are expanding their product offerings and giving their customers access to a wide range of cutting-edge and novel products using a variety of strategies. To gain market share, companies are expanding their range of products being offered. Industry participants use various growth methods, including collaborations, mergers and acquisitions, product launches, and development of new products, to bolster their positions in the market.
In December 2023, Carl Zeiss Meditec AG announced the agreement to acquire 100% shares of the Dutch Ophthalmic Research Center (DORC) from the France-based investment firm Eurazeo. The deal is valued at EUR 985 million and is expected to close in the first half of 2024. DORC's offer robust portfolio includes devices, disposables, and liquids for ophthalmic surgeries, with prime focus on its dual-function Eva Nexustm platform.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.